Nitric oxide donor molsidomine favors features of atherosclerotic plaque stability and reduces myocardial infarction in mice

Dare to Compare. Development of Atherosclerotic Lesions in Human, Mouse, and Zebrafish

“…While Van der Donckt et al reported no dead animals, which is consistent with our own experience, Stöhr et al published a 20% mortality and Johnson et al a mortality rate of 70% after 10 months on WTD ( 37 , 38 , 40 ). Other reports of WTD for shorter periods show the same variability in mortality rates ( 42 , 43 ). It is unclear whether this variation is a consequence of the ApoE KO or husbandry differences.…”

Exogenous NO Therapy for the Treatment and Prevention of Atherosclerosis

“…Further, molsidomine administration was associated with a reduction in plasma levels of ICAM-1 [32]. In a recent paper by Roth et al [33], the NO donor molsidomine administration in a murine model of atherosclerosis was associated with features of stability, including a thicker fibrous cap, increased occurrence of plaque macrocalcifications, reduced perivascular fibrosis. Even though survival was not affected, there was less evidence of neurological dysfunction, and the occurrence of myocardial infarctions was reduced significantly.…”

Research progress on toxicity, function, and mechanism of metal oxide nanoparticles on vascular endothelial cells

“…Mechanical stimulation of ECs triggers a complex of biochemical reactions involving multiple cellular mechanical sensors and enzymes, aimed at reactions at the activation of eNOS (Mehta, Zhou, Radulescu, & Besner, 2008). NO regulates vascular resistance and blood flow by stimulating the relaxation of vascular smooth muscles, eliminating free radicals, and preventing plaque formation (Roth et al, 2019; Tinken et al, 2009). Therefore, the release of NO maintains the normal operation of ECs in blood vessels.…”